Patents Assigned to Inovio Pharmaceuticals
-
Patent number: 10016497Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.Type: GrantFiled: November 26, 2014Date of Patent: July 10, 2018Assignees: THE TRUSTEES OF THE UNIVERSTIY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.Inventors: David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai
-
Patent number: 9993545Abstract: The present invention relates to synthetic, consensus foot-and-mouth disease virus (FMDV) immunogenic proteins and nucleic acid molecule encoding such proteins, to vaccines against FMDV, to methods for inducing immune responses against FMVD, to methods for distinguishing between individuals infected with FMDV versus those vaccinated against FMDV, and methods of prophylactically and/or therapeutically immunizing individuals against FMDV.Type: GrantFiled: March 17, 2014Date of Patent: June 12, 2018Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.Inventors: David B. Weiner, Jian Yan, Karuppiah Muthumani, Niranjan Y. Sardesai
-
Patent number: 9987347Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide, such as a consensus dengue prME that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all 4 dengue subtypes.Type: GrantFiled: March 14, 2014Date of Patent: June 5, 2018Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.Inventors: David B. Weiner, Jian Yan, Niranjan Sardesai
-
Publication number: 20170266282Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.Type: ApplicationFiled: December 1, 2015Publication date: September 21, 2017Applicants: Inovio Pharmaceuticals, Inc., The Trustees of the University of PennsylvaniaInventors: David B. Weiner, Karuppiah Muthumani, Seleeke Flingai, Niranjan Sardesai
-
Patent number: 9669091Abstract: Disclosed herein is a vaccine comprising an antigen and IL-23. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.Type: GrantFiled: March 13, 2014Date of Patent: June 6, 2017Assignees: INOVIO PHARMACEUTICALS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: David B. Weiner, Jian Yan, Matthew Morrow, Bernadette Ferraro, David Hokey
-
Patent number: 9446112Abstract: The invention relates to compositions and methods for treating C. difficile associated disease (CDAD) through the administration to a subject in need thereof at least one nucleic acid encoding at least a portion of at least one of toxin A and toxin B.Type: GrantFiled: July 12, 2012Date of Patent: September 20, 2016Assignees: Philadelphia Health & Education Corporation, Inovio Pharmaceuticals, Inc., The Trustees of the University of PennsylvaniaInventors: Michele Kutzler, Scott Baliban, David B. Weiner, Niranjan Y. Sardesai, J. Joseph Kim
-
Patent number: 9446114Abstract: The invention relates to DNA vaccines that target multiple arenavirus agents singly or simultaneously.Type: GrantFiled: July 11, 2012Date of Patent: September 20, 2016Assignee: Inovio Pharmaceuticals, Inc.Inventors: Kate Broderick, Niranjan Sardesai, Kathleen Cashman, Connie Schmaljohn
-
Patent number: 9399056Abstract: Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided.Type: GrantFiled: November 24, 2014Date of Patent: July 26, 2016Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David B. Weiner, Jian Yan, Bernadette Ferraro, Niranjan Y. Sardesai, Mathura P. Ramanathan
-
Patent number: 9156890Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a/1b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.Type: GrantFiled: September 8, 2014Date of Patent: October 13, 2015Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David B. Weiner, Krystle A. Lang, Jian Yan, Ruxandra Draghia-Akli, Amir Khan
-
Patent number: 9156891Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.Type: GrantFiled: November 24, 2014Date of Patent: October 13, 2015Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David B. Weiner, Krystle A. Lang-Kuhs, Jian Yan, Ruxandra Draghia-Akli, Amir S. Khan
-
Publication number: 20150284448Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.Type: ApplicationFiled: December 13, 2013Publication date: October 8, 2015Applicant: Inovio Pharmaceuticals, Inc.Inventors: David B. Weiner, Karuppiah Muthumani, Niranjan Sardesai, Seleeke Flingai
-
Patent number: 9109014Abstract: Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.Type: GrantFiled: November 2, 2010Date of Patent: August 18, 2015Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David B Weiner, Bernadette Ferraro, Jian Yan, Patricia A Brown, Rodney A Bowling, Douglas R Kern, Mathura P Ramanathan, Niranjan Y Sardesai, Karuppiah Muthumani
-
Patent number: 9034313Abstract: Nucleic acid molecules comprising a nucleotide sequence encoding RANTES and fragments and variants thereof are disclosed. Additionally, nucleic acid molecules and compositions comprising the nucleotide sequence encoding RANTES and fragments and variants thereof in combination with nucleic acid sequences encoding immunogens are provided. Recombinant viral vectors comprising the nucleotide sequence encoding RANTES and fragments and variants thereof with or without a nucleic acid sequence encoding immunogens are also provided as are live attenuated pathogens comprising a nucleotide sequence encoding RANTES and fragments and variants thereof. Methods of modulating immune responses and of inducing an immune response against an immunogen are also disclosed.Type: GrantFiled: February 8, 2011Date of Patent: May 19, 2015Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David B Weiner, Jean D Boyer, Michele Kutzler
-
Patent number: 8927692Abstract: Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided.Type: GrantFiled: November 14, 2011Date of Patent: January 6, 2015Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David B Weiner, Jian Yan, Bernadette Ferraro, Niranjan Y Sardesai, Mathura P Ramanathan
-
Patent number: 8921536Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.Type: GrantFiled: October 20, 2011Date of Patent: December 30, 2014Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David B Weiner, Krystle Lang, Jian Yan, Ruxandra Draghia-Akli, Amir S Khan
-
Publication number: 20140341936Abstract: The invention relates to compositions and methods for treating C. difficile associated disease (CDAD) through the administration to a subject in need thereof at least one nucleic acid encoding at least a portion of at least one of toxin A and toxin B.Type: ApplicationFiled: July 12, 2012Publication date: November 20, 2014Applicants: Inovio Pharmaceuticals, Inc., Philadelphia Health & Education Corporation d/b/a Drexel University College of MedicineInventors: Michele Kutzler, Scott Baliban, David B. Weiner, Niranjan Y. Sardesai, J. Joseph Kim
-
Patent number: 8829174Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1 a/1 b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.Type: GrantFiled: October 29, 2008Date of Patent: September 9, 2014Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David B Weiner, Krystle A. Lang Kuhs, Jian Yan, Ruxandra Draghia-Akli, Amir Khan
-
Patent number: 8535687Abstract: The present invention relates to DNA vaccines that are capable of generating a protective immune response in mammals against a pox virus, and comprises at least one DNA plasmid capable of expressing a plurality of VACV MV antigens, and at least one DNA plasmid capable of expressing a plurality of VACV EV antigens. Also, the present invention relates to methods of inducing a protective immune response in a mammal to pox virus, including a neutralizing antibody response, comprising: injecting into tissue of said mammal said DNA vaccine.Type: GrantFiled: May 28, 2009Date of Patent: September 17, 2013Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: Ruxandra Draghia-Akli, Jon Prigge, Niranjan Y. Sardesai, David B. Weiner, Lauren A. Hirao
-
Publication number: 20110262394Abstract: Aspects of the present invention relate to isolated nucleic acids that encode a consensus DIII domain of protein E and vaccines made using same, and also methods for using the aforementioned to generate in a host an immune response against multiple serotypes of flavivirus, particularly West Nile virus and Japanese encephalitis virus.Type: ApplicationFiled: November 17, 2009Publication date: October 27, 2011Applicant: INOVIO PHARMACEUTICALS, INC.Inventors: Mathura P. Ramanathan, Niranjan Y. Sardesai